Search results
Results from the WOW.Com Content Network
Naltrexone/bupropion, sold under the brand name Contrave among others, is a fixed-dose combination medication for the management of chronic obesity in adults in combination with a reduced-calorie diet and increased physical activity. [4] [6] It contains naltrexone, an opioid antagonist, and bupropion, an aminoketone atypical antidepressant. [4]
Naltrexone, sold under the brand name Revia among others, is a medication primarily used to manage alcohol use or opioid use disorder by reducing cravings and feelings of euphoria associated with substance use disorder. [8] It has also been found effective in the treatment of other addictions and may be used for them off-label. [12]
Multiple studies have shown that low-dose naltrexone has promise as a treatment for chronic pain, some autoimmune disorders and cancers. [8] [9] [10] As of 2014, no peer-reviewed studies supporting low-dose naltrexone for multiple sclerosis (MS) have been published. [11] [12] Clinical trials for treatment of fibromyalgia were initiated in 2021 ...
This page was last edited on 8 February 2024, at 12:44 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
(+)-Naloxone (dextro-naloxone) is a drug which is the opposite enantiomer of the opioid antagonist drug (−)-naloxone.Unlike (−)-naloxone, (+)-naloxone has no significant affinity for opioid receptors, [1] but instead has been discovered to act as a selective antagonist of Toll-like receptor 4.
Nalmefene, sold under the brand name Revex among others, is a medication that is used in the treatment of opioid overdose and alcohol dependence. [2] [3] Nalmefene belongs to the class of opioid antagonists and can be taken by mouth, administered by injection, or delivered through nasal administration.
Noroxycodone is the major metabolite of the opioid analgesic oxycodone. [1] [2] [3] It is formed from oxycodone in the liver via N-demethylation predominantly by CYP3A4.[1] [2] [3] Noroxycodone binds to and activates the μ-opioid receptor (MOR) similarly to oxycodone, although with one-third of the affinity of oxycodone and 5- to 10-fold lower activational potency.
The California Department of Transportation has developed a similar test, California Test 216, which measures the maximum wet density, and controls the compactive effort based on the length (in fact the height) of the test sample and not on its volume. The primary advantage of this test is that maximum density test results are available sooner ...